Skip to main content

Andexanet Alfa Use in Patients Requiring Cardiopulmonary Bypass: Quo Vadis?

Publication ,  Journal Article
Levy, JH; Welsby, I
Published in: A A Pract
December 15, 2019

Duke Scholars

Published In

A A Pract

DOI

EISSN

2575-3126

Publication Date

December 15, 2019

Volume

13

Issue

12

Start / End Page

477

Location

United States

Related Subject Headings

  • Recombinant Proteins
  • Pyridones
  • Pyrazoles
  • Patients
  • Humans
  • Factor Xa
  • Cardiopulmonary Bypass
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Levy, J. H., & Welsby, I. (2019). Andexanet Alfa Use in Patients Requiring Cardiopulmonary Bypass: Quo Vadis? A A Pract, 13(12), 477. https://doi.org/10.1213/XAA.0000000000001115
Levy, Jerrold H., and Ian Welsby. “Andexanet Alfa Use in Patients Requiring Cardiopulmonary Bypass: Quo Vadis?A A Pract 13, no. 12 (December 15, 2019): 477. https://doi.org/10.1213/XAA.0000000000001115.
Levy JH, Welsby I. Andexanet Alfa Use in Patients Requiring Cardiopulmonary Bypass: Quo Vadis? A A Pract. 2019 Dec 15;13(12):477.
Levy, Jerrold H., and Ian Welsby. “Andexanet Alfa Use in Patients Requiring Cardiopulmonary Bypass: Quo Vadis?A A Pract, vol. 13, no. 12, Dec. 2019, p. 477. Pubmed, doi:10.1213/XAA.0000000000001115.
Levy JH, Welsby I. Andexanet Alfa Use in Patients Requiring Cardiopulmonary Bypass: Quo Vadis? A A Pract. 2019 Dec 15;13(12):477.

Published In

A A Pract

DOI

EISSN

2575-3126

Publication Date

December 15, 2019

Volume

13

Issue

12

Start / End Page

477

Location

United States

Related Subject Headings

  • Recombinant Proteins
  • Pyridones
  • Pyrazoles
  • Patients
  • Humans
  • Factor Xa
  • Cardiopulmonary Bypass